Amicus Therapeutics, Inc. (NASDAQ:FOLD) has announced that it would be acquiring Scioderm Inc. a company focused on developing therapies to treat rare diseases. Scioderm, currently has its lead drug candidate for Epidermolysis Bullosa in phase-3 of clinical trials. Furthermore, the acquisition would help…